Detalhe da pesquisa
1.
Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
Prostate
; 78(6): 435-445, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29431193
2.
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 25(6): 1766-1773, 2019 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30209161
3.
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.
Genome Med
; 10(1): 85, 2018 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30458854
4.
Changes in Body Image in Patients with Prostate Cancer over 2 Years of Treatment with a Gonadotropin-Releasing Hormone Analogue (Triptorelin): Results from a Belgian Non-Interventional Study.
Drugs Real World Outcomes
; 3(2): 183-190, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27398297
5.
The use of a Meckel's diverticulum in the creation of an orthotopic neobladder in case of a short mesoileum: a case report.
Adv Urol
; : 493236, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19859565